ipm001
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05105815)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05536427 | Phase 1 | Oct 1, 2022 | Beijing Boren Hospital, Beijing Immupeutics Medicine Technology Limited, Chinese Academy of Medical Sciences |
| NCT05105815 | Early Phase 1 (Phase 1) | Dec 31, 2021 | Beijing Immupeutics Medicine Technology Limited, Fudan University, Peking University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Immupeutics Medicine Technology Limited | For profit | 2 | 0 | 1 | 2021 |
| Beijing Boren Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1